-+ 0.00%
-+ 0.00%
-+ 0.00%

Tiziana reports preclinical data showing intranasal foralumab eases Long COVID brain inflammation in mice

PUBT·04/16/2026 11:00:41
Listen to the news
Tiziana reports preclinical data showing intranasal foralumab eases Long COVID brain inflammation in mice
  • Tiziana Life Sciences disclosed positive preclinical results for intranasal foralumab in a bioRxiv preprint published April 16, 2026; findings have already been presented in that publication.
  • Mouse-model study showed treatment reduced Long COVID-linked neuroinflammation, supported brain repair processes, and improved cognitive function.
  • Data also indicated Long COVID patients with neurological symptoms had lower circulating regulatory T-cell levels, supporting clinical relevance of immune-modulating approach.
  • Tiziana positioned results as mechanistic support for ongoing intranasal foralumab development across multiple neuroinflammatory and neurodegenerative programs.
  • Company noted prior expanded-access use in non-active secondary progressive multiple sclerosis showed favorable safety with signals of clinical benefit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604160700PRIMZONEFULLFEED9691169) on April 16, 2026, and is solely responsible for the information contained therein.